trending Market Intelligence /marketintelligence/en/news-insights/trending/a6H9G5qw_NioZm2sa6q0iw2 content esgSubNav
In This List

UK drugs association drops legal battle over new cost constraints

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints


UK drugs association drops legal battle over new cost constraints

The Association of the British Pharmaceutical Industry's board unanimously agreed to not appeal a high court's decision to turn down its application for a judicial review of the National Institute for Health and Care Excellence's new cost rules for drugs.

Previously, the trade association of biopharmaceutical companies in the U.K. sought to challenge NICE's policy that limits funding of drugs expected to cost the U.K.'s National Health Service more than £20 million per year in any of the first three years of use.

The application was rejected by High Court Honourable Justice Elisabeth Laing.